AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AVEO
Previous Symbol
CUSIP05358810
Phone617-588-1960
Debt
Debt-to-Equity RatioN/A
Current Ratio1.10
Quick Ratio1.16
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.58 million
Price / Sales31.25
Cash FlowN/A
Price / CashN/A
Book Value($0.48) per share
Price / Book-3.94
Profitability
EPS (Most Recent Fiscal Year)($0.16)
Net Income$-65,020,000.00
Net Margins-590.02%
Return on EquityN/A
Return on Assets-54.94%
Miscellaneous
Employees19
Outstanding Shares125,350,000
Market Cap$236.91 million
OptionableOptionable
AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions
What is AVEO Pharmaceuticals' stock symbol?
AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
How were AVEO Pharmaceuticals' earnings last quarter?
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.00. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.98 million. View AVEO Pharmaceuticals' Earnings History.
When is AVEO Pharmaceuticals' next earnings date?
What price target have analysts set for AVEO?
3 Wall Street analysts have issued twelve-month target prices for AVEO Pharmaceuticals' shares. Their predictions range from $5.00 to $9.00. On average, they anticipate AVEO Pharmaceuticals' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 270.4% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.
What is the consensus analysts' recommendation for AVEO Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AVEO Pharmaceuticals.
Has AVEO Pharmaceuticals been receiving favorable news coverage?
News stories about AVEO stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AVEO Pharmaceuticals earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Are investors shorting AVEO Pharmaceuticals?
AVEO Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 22,599,619 shares, an increase of 18.2% from the October 15th total of 19,120,393 shares. Based on an average daily trading volume, of 2,980,606 shares, the days-to-cover ratio is presently 7.6 days. Currently, 23.2% of the shares of the stock are sold short. View AVEO Pharmaceuticals' Current Options Chain.
Who are some of AVEO Pharmaceuticals' key competitors?
Some companies that are related to AVEO Pharmaceuticals include Rhythm Pharmaceuticals (RYTM), Alder Biopharmaceuticals (ALDR), Intra-Cellular Therapies (ITCI), Lexicon Pharmaceuticals (LXRX), Uniqure (QURE), Akorn (AKRX), Kiniksa Pharmaceuticals (KNSA), Puma Biotechnology (PBYI), Aptinyx (APTX), ImmunoGen (IMGN), Y-mAbs Therapeutics (YMAB), Dicerna Pharmaceuticals (DRNA), Clovis Oncology (CLVS), Viking Therapeutics (VKTX) and Deciphera Pharmaceuticals (DCPH).
Who are AVEO Pharmaceuticals' key executives?
AVEO Pharmaceuticals' management team includes the folowing people:
- Mr. Michael P. Bailey, CEO, Pres & Director (Age 53)
- Mr. Matthew D. Dallas, Chief Financial Officer (Age 43)
- Dr. Michael N. Needle, Chief Medical Officer (Age 58)
- Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 59)
- Dr. Emile Farhan Ph.D., VP of Technical Operations
Who are AVEO Pharmaceuticals' major shareholders?
AVEO Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include NEA Management Company LLC (15.71%), BlackRock Inc. (5.98%), Bank of New York Mellon Corp (0.28%), Fosun International Ltd (0.26%), X Square Capital LLC (0.24%) and Teachers Advisors LLC (0.18%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.
Which institutional investors are selling AVEO Pharmaceuticals stock?
Which institutional investors are buying AVEO Pharmaceuticals stock?
AVEO stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Fosun International Ltd, BlackRock Inc., Teachers Advisors LLC, MetLife Investment Advisors LLC, Wells Fargo & Company MN, X Square Capital LLC and Bank of New York Mellon Corp. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.
How do I buy shares of AVEO Pharmaceuticals?
Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AVEO Pharmaceuticals' stock price today?
One share of AVEO stock can currently be purchased for approximately $1.89.
How big of a company is AVEO Pharmaceuticals?
AVEO Pharmaceuticals has a market capitalization of $239.41 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.
What is AVEO Pharmaceuticals' official website?
How can I contact AVEO Pharmaceuticals?
AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]
MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
